The China Mail - Aspire Biopharma Holdings, Inc., Announces Public Listing on Nasdaq

USD -
AED 3.672501
AFN 63.493369
ALL 83.065121
AMD 368.061373
ANG 1.790403
AOA 917.503082
ARS 1479.268799
AUD 1.450705
AWG 1.80125
AZN 1.704306
BAM 1.724631
BBD 2.015008
BDT 123.052911
BGN 1.69088
BHD 0.377235
BIF 2981.376318
BMD 1
BND 1.298014
BOB 6.913275
BRL 5.202301
BSD 1.000494
BTN 94.394378
BWP 13.651955
BYN 2.847191
BYR 19600
BZD 2.012169
CAD 1.42401
CDF 2269.000106
CHF 0.813199
CLF 0.023389
CLP 920.249899
CNY 6.7905
CNH 6.80507
COP 3440.62
CRC 455.363127
CUC 1
CUP 26.5
CVE 97.231163
CZK 21.38355
DJF 178.15793
DKK 6.59032
DOP 58.957356
DZD 133.564019
EGP 49.534796
ERN 15
ETB 157.79172
EUR 0.88172
FJD 2.244203
FKP 0.75995
GBP 0.759865
GEL 2.640163
GGP 0.75995
GHS 11.25259
GIP 0.75995
GMD 72.510374
GNF 8766.88653
GTQ 7.632888
GYD 209.329395
HKD 7.840575
HNL 26.770661
HRK 6.645899
HTG 130.762583
HUF 313.477965
IDR 17982
ILS 2.975899
IMP 0.75995
INR 94.38045
IQD 1310.623964
IRR 1375050.000123
ISK 126.960185
JEP 0.75995
JMD 157.684032
JOD 0.708978
JPY 161.850226
KES 129.59298
KGS 87.450161
KHR 4028.922887
KMF 433.999516
KPW 900.00035
KRW 1542.979919
KWD 0.30971
KYD 0.833737
KZT 484.885895
LAK 22235.351175
LBP 89595.167762
LKR 337.175056
LRD 182.081919
LSL 16.568199
LTL 2.95274
LVL 0.60489
LYD 6.424817
MAD 9.418715
MDL 17.758476
MGA 4265.244037
MKD 54.366184
MMK 2099.534862
MNT 3583.823146
MOP 8.07945
MRU 39.739339
MUR 48.190398
MVR 15.449729
MWK 1734.844143
MXN 17.638795
MYR 4.117302
MZN 63.909585
NAD 16.568199
NGN 1379.810012
NIO 36.814468
NOK 9.891199
NPR 151.027498
NZD 1.773553
OMR 0.384501
PAB 1.000485
PEN 3.423701
PGK 4.390498
PHP 61.322498
PKR 278.431272
PLN 3.78022
PYG 6113.48706
QAR 3.646841
RON 4.613097
RSD 103.466046
RUB 75.497985
RWF 1470.217363
SAR 3.75631
SBD 8.051953
SCR 14.057553
SDG 600.000277
SEK 9.75957
SGD 1.297675
SHP 0.746601
SLE 24.792558
SLL 20969.503664
SOS 571.756095
SRD 37.459846
STD 20697.981008
STN 21.604176
SVC 8.754541
SYP 110.532098
SZL 16.56607
THB 33.402522
TJS 9.249239
TMT 3.5
TND 2.970618
TOP 2.40776
TRY 46.51525
TTD 6.795175
TWD 31.850502
TZS 2618.939032
UAH 44.986949
UGX 3701.80946
UYU 40.139678
UZS 12018.0946
VES 620.752985
VND 26320
VUV 119.820737
WST 2.777776
XAF 578.419823
XAG 0.017474
XAU 0.000251
XCD 2.70255
XCG 1.803071
XDR 0.718004
XOF 578.424923
XPF 105.161521
YER 238.625026
ZAR 16.561795
ZMK 9001.203975
ZMW 18.058287
ZWL 321.999592
  • CMSD

    -0.1200

    21.9

    -0.55%

  • RBGPF

    0.0000

    61.3

    0%

  • CMSC

    0.0550

    22.12

    +0.25%

  • BCC

    1.5300

    79.19

    +1.93%

  • GSK

    1.2100

    52.3

    +2.31%

  • BCE

    -0.2250

    22.975

    -0.98%

  • NGG

    0.8750

    83.705

    +1.05%

  • BTI

    0.6750

    62.065

    +1.09%

  • RYCEF

    0.7500

    19

    +3.95%

  • RELX

    0.1700

    31.32

    +0.54%

  • VOD

    -0.0100

    13.8

    -0.07%

  • RIO

    1.0900

    95.12

    +1.15%

  • AZN

    3.0500

    186.07

    +1.64%

  • JRI

    0.0500

    12.62

    +0.4%

  • BP

    0.0400

    37.9

    +0.11%

Aspire Biopharma Holdings, Inc., Announces Public Listing on Nasdaq
Aspire Biopharma Holdings, Inc., Announces Public Listing on Nasdaq

Aspire Biopharma Holdings, Inc., Announces Public Listing on Nasdaq

NEW YORK CITY, NY / ACCESS Newswire / February 19, 2025 / Aspire Biopharma, Inc. ("Aspire" or the "Company"), a developer of a multi-faceted patent-protected disruptive drug delivery mechanism technology, and PowerUp Acquisition Corp. (Nasdaq:PWUP), a Nasdaq Global Market® listed special purpose acquisition company, ("PowerUp"), today announced the completion of their previously announced business combination (the "Business Combination"). The Business Combination was approved by PowerUp Acquisition Corp. stockholders on January 31, 2025, and it closed on February 17, 2025. Beginning on February 20, 2025, Aspire Biopharma shares of common stock and warrants will begin to trade on the Nasdaq Global Market and Nasdaq Capital Market (collectively, "Nasdaq"), respectively, under the ticker symbols "ASBP" and "ASBPW," respectively.

Text size:

The Business Combination is expected to provide Aspire Biopharma with improved access to sources of new capital, enable Aspire to further expand the internal development of new product offerings, accelerate strategic partnerships, and fast-absorbing aspirin for use in stopping cardiac incidents which management believes is a candidate for fast-track approval through the FDA.

About this Transaction

On September 23, 2024, Aspire Biopharma, Inc., a developer of a multi-faceted patent protected disruptive drug delivery mechanism technology, entered into a definitive business combination agreement with PowerUp Acquisition Corp. (Nasdaq:PWUP), a Nasdaq Global Market® listed special purpose acquisition company. Under the terms of the business combination agreement, the SPAC Sponsors and certain current equity holders, officers and directors of Aspire Biopharma have agreed to be subject to a (term) lockup in respect of their common stock, in each case subject to certain customary exceptions, which will provide important stability to the leadership and governance of the combined entity.

The description of the business combination contained herein is only a high-level summary and is qualified in its entirety by the more detailed description of the terms of the transaction provided in the definitive proxy statement/prospectus filed with the U.S. Securities and Exchange Commission on January 14, 2025.

Advisors

Dykema Gossett, PLLC served as legal counsel to PowerUp Acquisition Corp.

Sichenzia Ross Ference Carmel LLP served as legal counsel to Aspire BioPharma, Inc.

About Aspire Biopharma, Inc.

Headquartered in Humacao, Puerto Rico, Aspire Biopharma has developed a disruptive technology through a Novel Soluble Formulation which addresses emergencies, drug efficacy, dosage management, and response time. For more information, please visit www.aspirebiolabs.com.

About PowerUp Acquisition Corp.

PowerUp Acquisition Corp. is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The PowerUp management team is led by Mr. Surendra Ajjarapu, Chief Executive Officer.

Safe Harbor Statement

Certain statements made in this communication are "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may generally be identified by the use of words such as "estimate," "projects," "expects," "anticipates," "forecasts," "plans," "intends," "believes," "seeks," "may," "will," "would," "should," "future," "propose," "potential," "target," "goal," "objective," "outlook" and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding the financial position, business strategy and the plans and objectives of management for future operations of the combined public company, including as they relate to the potential Business Combination and related transactions, pricing and market opportunity, the completion of the potential Business Combination and related transactions, the level of redemptions by PowerUp's public shareholders and the timing of the completion of the proposed Business Combination, including the anticipated closing date of the proposed Business Combination and the use of the cash proceeds therefrom. These statements are based on various assumptions, whether or not identified in this communication, and on the current expectations of PowerUp's and Aspire's management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on by any investor as a guarantee, an assurance, a prediction or a definitive statement of fact or probability. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside the control of the parties, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. Information concerning factors that could cause PowerUp's actual results to differ materially from those contained in these forward-looking statements can be found in the Company's Annual Report on Form 10-K, subsequent quarterly reports on Form 10-Q and initial public offering prospectus. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

Aspire Biopharma, Inc. Contact

TraDigital IR
Kevin McGrath
+1-646-418-7002
[email protected]

Powerup Acquisition Corp. Contact:

Suren Ajjarapu
Chairman and Chief Executive Officer
[email protected]
347-313-8109

SOURCE: Aspire Biopharma, Inc.



View the original press release on ACCESS Newswire

W.Tam--ThChM